Skip to main content
SpringerLink
Log in

Nonsurgical Management of Gallbladder Cancer

  • Living reference work entry
  • First Online:
Hepato-Pancreato-Biliary Malignancies

  • 41 Accesses

Abstract

Gallbladder cancer is an uncommon malignancy and historically thought to have a poor prognosis. Nevertheless, interdisciplinary approaches to care and the advent of precision medicine have improved overall survival outcomes. Most agree that for patients with at least Stage IB disease, adjuvant chemotherapy and chemoradiation therapy improve overall survival. There are no standard guidelines for adjuvant radiation, but many agree to perform adjuvant radiation for R1 disease. Modern chemotherapy protocols have improved response rates for locally advanced disease; yet no clear guidelines for neoadjuvant therapy have been established. External beam, stereotactic radiation, and brachytherapy can provide local palliation and improve hyperbilirubinemia. Gemcitabine- and 5-FU-based chemotherapy combinations have long demonstrated activity in this disease; however, targeted therapy approaches including immunotherapy will serve as new treatment modalities in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Survival rates for gallbladder cancer. 2021. https://www.cancer.org/cancer/gallbladder-cancer/detection-diagnosis-staging/survival-rates.html.

  2. Maruyama S, et al. Indications for extrahepatic bile duct resection due to perineural invasion in patients with gallbladder cancer. World J Surg Oncol. 2019;17(1):200.

    Article  Google Scholar 

  3. Hatzeras I, et al. Elevated CA 19-9 levels portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford). 2010;12(2):134–8.

    Article  Google Scholar 

  4. Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81:e853–9.

    Article  Google Scholar 

  5. Horgan AM, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934.

    Article  Google Scholar 

  6. Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010;78:194–8.

    Article  Google Scholar 

  7. Wang SJ, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;20(35):4627.

    Article  Google Scholar 

  8. Ben-Josef E, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617.

    Article  CAS  Google Scholar 

  9. Primrose J, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.

    Article  CAS  Google Scholar 

  10. Nakamura M, et al. Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. Anticancer Res. 2014;34(6):3125–9.

    PubMed  CAS  Google Scholar 

  11. Hakeen A, et al. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer – a systematic review. Eur J Surg Oncol. 2019;45:83–91.

    Article  Google Scholar 

  12. Shroff R, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers. A phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–30.

    Article  Google Scholar 

  13. Polistina FA, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, nonmetastatic, locally advanced hilar cholangiocarcinoma. Radiother Oncol. 2011;99:120–3.

    Article  CAS  Google Scholar 

  14. Momm F, et al. Stereotactic fractionated radiotherapy for Klatskin’s tumors. Radiother Oncol. 2010;95:99–102.

    Article  Google Scholar 

  15. Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273.

    Article  CAS  Google Scholar 

  16. Kim ST, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019;30(5):788.

    Article  CAS  Google Scholar 

  17. Lamarca A, et al. ABC-06. A randomized phase III, multicentre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients with locally advanced/metastatic biliary tract cancers (ABC) previous-treated with cisplatin/gemcitabine chemotherapy. J Clin Oncol. 2019;37(Suppl 15):4003.

    Google Scholar 

  18. Valle JW, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–62.

    Article  CAS  Google Scholar 

  19. Javle M, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.

    Article  CAS  Google Scholar 

  20. Patel A, et al. Genomic landscape and targeted treatment of gallbladder cancer: results of a first ongoing prospective study. South Asian J Cancer. 2020;9(2):74–9.

    Article  Google Scholar 

  21. Li M, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1 mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68(6):1024–33.

    Article  CAS  Google Scholar 

  22. Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.

    Article  CAS  Google Scholar 

  23. Drilon A, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.

    Article  CAS  Google Scholar 

  24. Verlingue L, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-1 trial. Eur J Cancer. 2017;87:122.

    Article  Google Scholar 

  25. Kim RD, et al. A phase 2 multi-institutional study of nivolumab for patient with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888.

    Article  Google Scholar 

  26. Klein O, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020;6(9):1405.

    Article  Google Scholar 

  27. Silva VWK, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol. 2016;5(5):62.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Capital Health Cancer Center, Pennington, NJ, USA

    Neel Gandhi & Timothy Chen

Authors
  1. Neel Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neel Gandhi .

Editor information

Editors and Affiliations

  1. Medical Director, Capital Health Medical Center Hopewell, Pennington, NJ, USA

    Cataldo Doria

  2. Capital Health Center for Digestive Health, Pennington, NJ, USA

    Jason N. Rogart

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Gandhi, N., Chen, T. (2021). Nonsurgical Management of Gallbladder Cancer. In: Doria, C., Rogart, J.N. (eds) Hepato-Pancreato-Biliary Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-37482-2_24-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-37482-2_24-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-37482-2

  • Online ISBN: 978-3-030-37482-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation